AAIC 2012: Baxter's (BAX +1%) Gammagard immune system therapy for Alzheimer's disease performed well in Phase 2 trials, with 4 patients who received the most effective dose experiencing a stabilization over 3 years. It's all very small scale, and the proof will come early next year with the results of a larger Phase 3 study, but it's still really encouraging.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Feb 2, 2015)
at Investor's Business Daily (Jan 16, 2015)
at Investor's Business Daily (Jan 8, 2015)
at CNBC.com (Jan 6, 2015)
at Investor's Business Daily (Jan 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs